Back
Business
NEW DELHI: Ranbaxy Laboratories on Wednesday has entered into an exclusive licensing agreement with the U.S.-based BioPro Pharmaceuticals for marketing and distributing its drug ‘Gliadel Wafer’ used for treating brain tumor. The company has also received import permission for marketing ‘Gliadel Wafer’ in India. © Copyright 2000 - 2009 The Hindu |